Scholar Rock Holding Corporation Overview
Pro stress-test →Scholar Rock is a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health. The company views 2026 as a transformative year, executing with urgency across rare, severe neuromuscular disease programs as it builds its foundation to become a global biotech powerhouse.
Strategic Profile
Pro stress-test →As the first and only company to deliver a successful Phase 3 study with a myostatin inhibitor, Scholar Rock is building a robust pipeline of anti-myostatin product candidates to serve patients by addressing a broad range of rare, severe, and debilitating neuromuscular diseases. The 2026 strategy centers on securing U.S. and European regulatory approvals and commercial launch for apitegromab in children and adults with SMA, expanding development of apitegromab into infants under two years of age and FSHD, and advancing its broader anti-myostatin pipeline including subcutaneous apitegromab and SRK-439.
Competitive Landscape
Pro stress-test →Primary competitors include Blueprint Medicines, Caribou Biosciences, Arcus Biosciences, Sagimet Biosciences, and Bristol-Myers Squibb among 41 competitors in the biotech space. Scholar Rock's differentiation rests on its proprietary anti-myostatin platform and first-and-only successful Phase 3 myostatin inhibitor study, positioning it uniquely for rare neuromuscular disease treatment.
Industry Context
Scholar Rock Holding Corporation operates in Biopharmaceutical - Clinical-Stage / Neuromuscular Rare Disease.
Key facts
Founded: 2012 · Headquarters: Cambridge, US · Market cap: $4.52B